Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adventrx Turns Focus From CoFactor To Vinorelbine, Docetaxel After Phase IIb Failure In CRC

This article was originally published in The Pink Sheet Daily

Executive Summary

CoFactor/5-FU arm fails to demonstrate significantly improved safety over leucovorin/5-FU in treatment of metastatic colorectal cancer, but method of administration may make a difference, CEO says.

You may also be interested in...



Adventrx Finds Success In Vinorelbine Emulsion Study After CoFactor Failure

Firm is on track to submit ANX-530 505(b)(2) new drug application with data showing bioequivalence to GSK’S Navelbine in 2008.

Adventrx Finds Success In Vinorelbine Emulsion Study After CoFactor Failure

Firm is on track to submit ANX-530 505(b)(2) new drug application with data showing bioequivalence to GSK’S Navelbine in 2008.

Adventrx Halts Phase III Study Of CoFactor In Metastatic Colorectal Cancer

Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel